Last reviewed · How we verify
Anti-FLT3 CAR-T cells
At a glance
| Generic name | Anti-FLT3 CAR-T cells |
|---|---|
| Also known as | HG-CT-1 |
| Sponsor | Hemogenyx Pharmaceuticals LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-FLT3 CAR-T cells CI brief — competitive landscape report
- Anti-FLT3 CAR-T cells updates RSS · CI watch RSS
- Hemogenyx Pharmaceuticals LLC portfolio CI